Seeing the Future Through Science
July 7th, 2020 NEWPORT BEACH, Calif.–(BUSINESS WIRE)– jCyte Inc., a biotech company dedicated to preserving andrestoring vision in patients with retinitis pigmentosa and other degenerative […]
NEWPORT BEACH, Calif.–(BUSINESS WIRE)– jCyte Inc., a biotech company dedicated to improving thelives of patients with rare degenerative retinal diseases, announced today its Scientific Advisory […]
UCI Beall Applied Innovation June 4, 2020 By Ethan Perez UCI company jCyte, Inc. has formalized an exclusive licensing contract with Japanese pharmaceutical company Santen Pharmaceutical. jCyte, founded by Dr. […]
BioWorld Santen inks $252M license to Jcyte ocular cell therapy May 8, 2020 By Michael Fitzhugh Keen to address a rare vision-limiting disorder endured […]
jCyte Inc. Enters into Ex-US Licensing and Commercialization Agreement for jCell Therapy with Global Ophthalmology Leader Santen Pharmaceutical jCyte to receive up to $252 million, […]
This article discusses the scope and purpose of the special designation for Regenerative Medicine Advanced Therapies (RMAT) created by the passage of the 21st Century Cures […]
Cell therapy company jCyte has announced results from a phase 1/2a clinical trial for its investigational product, jCell, in retinitis pigmentosa (RP). Presented by David […]
In the past few months, jCyte has made a number of important announcements. In December, we received an $8.3 million grant from the California Institute […]
May 2, 2017 – Cell therapy company jCyte announced that the U.S. Food & Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for […]
Phase 2b study will investigate safety and efficacy of retinitis pigmentosa therapy April 19, 2017 – Cell therapy company jCyte is launching a phase […]